{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T12:30:45Z","timestamp":1745843445386,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T00:00:00Z","timestamp":1466553600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["The SAL-MPN registry had an initial funding from Novartis Pharma GmbH, N\u00fcrnberg, Germany."],"award-info":[{"award-number":["The SAL-MPN registry had an initial funding from Novartis Pharma GmbH, N\u00fcrnberg, Germany."]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00277-016-2730-y","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:29:08Z","timestamp":1466641748000},"page":"1399-1410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians"],"prefix":"10.1007","volume":"95","author":[{"name":"for the Study Alliance Leukemia (SAL)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kaifie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Hollburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Klausmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Maintz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Goekkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"G\u00f6thert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Geer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Serve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,22]]},"reference":[{"issue":"13","key":"2730_CR1","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122(13):2176\u20132184. doi: 10.1182\/blood-2013-03-460154","journal-title":"Blood"},{"issue":"5","key":"2730_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G (2008) Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia 22(5):905\u2013914. doi: 10.1038\/leu.2008.72","journal-title":"Leukemia"},{"issue":"4","key":"2730_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11899-013-0176-z","volume":"8","author":"G Finazzi","year":"2013","unstructured":"Finazzi G, De Stefano V, Barbui T (2013) Are MPNs vascular diseases? Curr Hematol Malig Rep 8(4):307\u2013316. doi: 10.1007\/s11899-013-0176-z","journal-title":"Curr Hematol Malig Rep"},{"key":"2730_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.6652","author":"M Hultcrantz","year":"2015","unstructured":"Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM, Derolf AR, Eloranta S, Samuelsson J, Landgren O, Dickman PW, Lambert PC, Bjorkholm M (2015) Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol Off J Am Soc Clin Oncol. doi: 10.1200\/JCO.2014.57.6652","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"24","key":"2730_CR5","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Bjorkholm M (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol Off J Am Soc Clin Oncol 30(24):2995\u20133001. doi: 10.1200\/JCO.2012.42.1925","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"2730_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ajh.23895","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Barbui T (2015) Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90(2):162\u2013173. doi: 10.1002\/ajh.23895","journal-title":"Am J Hematol"},{"issue":"3","key":"2730_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ajh.23135","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A (2012) Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87(3):285\u2013293. doi: 10.1002\/ajh.23135","journal-title":"Am J Hematol"},{"issue":"1","key":"2730_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N, Gokkurt E, Platzbecker U, Hollburg W, Gothert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brummendorf TH, Koschmieder S, Study Alliance L (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9(1):18. doi: 10.1186\/s13045-016-0242-9","journal-title":"J Hematol Oncol"},{"issue":"13","key":"2730_CR9","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901. doi: 10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"9","key":"2730_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, Pascutto C, Lazzarino M, Cazzola M, Tefferi A (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703\u20131708. doi: 10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"issue":"4","key":"2730_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol Off J Am Soc Clin Oncol 29(4):392\u2013397. doi: 10.1200\/JCO.2010.32.2446","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2730_CR12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119545","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S (2015a) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. doi: 10.3324\/haematol.2014.119545","journal-title":"Haematologica"},{"issue":"5","key":"2730_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015b) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435. doi: 10.1056\/NEJMoa1409002","journal-title":"N Engl J Med"},{"key":"2730_CR14","volume-title":"WHO classification of tumours of hematopoietic and lymphoid tissue","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of hematopoietic and lymphoid tissue. IARC, Lyon"},{"issue":"5","key":"2730_CR15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"issue":"3","key":"2730_CR16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","volume":"8","author":"S Cortelazzo","year":"1990","unstructured":"Cortelazzo S, Viero P, Finazzi G, D\u2019Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol Off J Am Soc Clin Oncol 8(3):556\u2013562","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"2730_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.blre.2012.06.002","volume":"26","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi MC, Finazzi G (2012b) Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 26(5):205\u2013211. doi: 10.1016\/j.blre.2012.06.002","journal-title":"Blood Rev"},{"key":"2730_CR18","unstructured":"Petrides PE, Baerlocher GM, Gisslinger H, Griesshammer M, Lengfelder E (2014) Essentielle (oder prim\u00e4re) Throm-bozyth\u00e4mie Leitlinie. DGHO Deutsche Gesellschaft f\u00fcr Haematologie und Medizinische Onkologie e.V. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/essentielle-oder-primaere-thrombozythaemie-et\/@@view\/html\/index.html . Accessed 25 Apr 2016"},{"issue":"26","key":"2730_CR19","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A (2012a) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128\u20135133 . doi: 10.1182\/blood-2012-07-444067 quiz 5252","journal-title":"Blood"},{"key":"2730_CR20","unstructured":"Lengfelder E, Baerlocher GM, Gisslinger H, Griesshammer M, Petrides PE (2016) Polycythaemia vera (PV). DGHO. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/polycythaemia-vera-pv\/@@view\/html\/index.html . Accessed 25 Apr 2016"},{"issue":"6","key":"2730_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A, European L (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol Off J Am Soc Clin Oncol 29(6):761\u2013770. doi: 10.1200\/JCO.2010.31.8436","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"2730_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomaus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Muller MC, Schweizerische Arbeitsgemeinschaft fur Klinische K, the German CMLSG (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126(1):42\u201349. doi: 10.1182\/blood-2015-01-617993","journal-title":"Blood"},{"issue":"1","key":"2730_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN landmark survey. BMC Cancer 16(1):167. doi: 10.1186\/s12885-016-2208-2","journal-title":"BMC Cancer"},{"issue":"16","key":"2730_CR24","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1182\/blood-2013-11-539742","volume":"123","author":"M Lauseker","year":"2014","unstructured":"Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CMLSG (2014) The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 123(16):2494\u20132496. doi: 10.1182\/blood-2013-11-539742","journal-title":"Blood"},{"issue":"51\u201352","key":"2730_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3238\/arztebl.2012.0893","volume":"109","author":"B Klimm","year":"2012","unstructured":"Klimm B, Brillant C, Skoetz N, Muller H, Engert A, Borchmann P (2012) The effect of specialized cancer treatment centers on treatment efficacy in Hodgkin\u2019s lymphoma. Dtsch Arztebl Int 109(51\u201352):893\u2013899. doi: 10.3238\/arztebl.2012.0893","journal-title":"Dtsch Arztebl Int"},{"issue":"9","key":"2730_CR26","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1371\/journal.pmed.0030341","volume":"3","author":"PN Papanikolaou","year":"2006","unstructured":"Papanikolaou PN, Christidi GD, Ioannidis JP (2006) Patient outcomes with teaching versus nonteaching healthcare: a systematic review. PLoS Med 3(9):e341. doi: 10.1371\/journal.pmed.0030341","journal-title":"PLoS Med"},{"issue":"3","key":"2730_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/ACM.0000000000000154","volume":"89","author":"AG Au","year":"2014","unstructured":"Au AG, Padwal RS, Majumdar SR, McAlister FA (2014) Patient outcomes in teaching versus nonteaching general internal medicine services: a systematic review and meta-analysis. Acad Med 89(3):517\u2013523. doi: 10.1097\/ACM.0000000000000154","journal-title":"Acad Med"},{"issue":"7","key":"2730_CR28","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/cncr.26474","volume":"118","author":"TD Shanafelt","year":"2012","unstructured":"Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, Schwager SM, Thompson CA, Bowen DA, Witzig TE, Slager SL, Call TG (2012) Hematologist\/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL). Cancer 118(7):1827\u20131837. doi: 10.1002\/cncr.26474","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2730-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2730-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2730-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T12:53:32Z","timestamp":1498308812000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2730-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,22]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2730"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2730-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2016,6,22]]}}}